Funding for this research was provided by:
Eli Lilly and Company (NA)
Received: 7 June 2019
Accepted: 9 October 2019
First Online: 12 November 2019
Ethics approval and consent to participate
: The medical ethics committees of the Medisch Spectrum Twente, Enschede and Isala, Zwolle hospitals determined, in accordance with Dutch law, that no ethical approval was required because all data were collected in the course of regular daily clinical practice. Nonetheless, patients were completely informed about the study, and informed consent was obtained from each patient. The DREAM remission induction cohort study is registered in the Netherlands Trial Register (NTR578).
: Not applicable.
: Walid Fakhouri, Inmaculada de la Torre, and Liliana Zaremba-Pechmann are employees and stockholders of Eli Lilly and Company. The other authors declare that they have no competing interests.